Research progress of CA125 and BDNF in serum of patients with acute myocardial infarction for predicting acute heart failure

作者：Haibo Wu, Kai Shao, Yun-Can Wang, Xuechao Wang, Huiliang Liu, Yuetao Xie, Rongpin Du · 发表于：Clinical Hemorheology and Microcirculation · 年份：2019 · DOI：10.3233/ch-190738 · 被引用次数：17 · 研究领域：Cardiac electrophysiology and arrhythmias、Cardiac Fibrosis and Remodeling、Cardiovascular Function and Risk Factors

BACKGROUND: At present, the treatment for acute myocardial infarction has achieved great progress. Reperfusion therapy in the short term can effectively reduce recurrence rates and mortality in patients with acute myocardial infarction. According to a report of a large national registry, the mortality of patients with acute coronary syndrome combined with acute heart failure is 10 times of that of patients without heart failure, and the mortality in nearly 10 years has no significant change. Therefore, people are constantly exploring indicators for acute heart failure prognosis to improve a patient's prognosis. With the constant understanding and exploration of acute myocardial infarction, more and more researches have focused in determining how to predict the occurrence of acute heart failure. The present study focuses on presenting the latest progress of Carbohydrate Antigen-125 (CA125) and Brain Derived Neurotrophic Factor (BDNF) in serum of patients with acute myocardial infarction in predicting acute heart failure.